Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia
Florian Huemer(Chinese University of Hong Kong), Lukas Weiß(Paracelsus Medical University), Christoph Grabmer(Paracelsus Medical University), Alexander Egle(Paracelsus Medical University), Richard Greil(Paracelsus Medical University), G Mayer(University of Salzburg), Thomas Melchardt(Paracelsus Medical University), Martin Dejaco(Paracelsus Medical University), Daniel Neureiter(Paracelsus Medical University)
Cited by 4
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Bim is a suppressor of Myc-induced mouse B cell leukemia
|Proceedings of the National Academy of Sciences|2004|482
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
|The Lancet Infectious Diseases|2021|344
Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas
|International Journal of Mass Spectrometry|2007|276